Arcus Biosciences (RCUS) Scheduled to Post Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) is set to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, February 21st. The company reported ($1.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.01. The business had revenue of $31.00 million for the quarter, compared to the consensus estimate of $28.30 million. Arcus Biosciences had a negative net margin of 262.39% and a negative return on equity of 57.17%. The firm’s quarterly revenue was down 8.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.93) EPS. On average, analysts expect Arcus Biosciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Trading Up 1.3 %

Shares of NYSE RCUS opened at $15.70 on Monday. The firm’s 50-day simple moving average is $17.25 and its 200 day simple moving average is $16.59. Arcus Biosciences has a 12-month low of $12.95 and a 12-month high of $25.47.

Insider Transactions at Arcus Biosciences

In related news, President Juan C. Jaen sold 3,900 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the transaction, the president now directly owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, President Juan C. Jaen sold 3,900 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $20.06, for a total value of $78,234.00. Following the completion of the transaction, the president now directly owns 1,211,365 shares of the company’s stock, valued at $24,299,981.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jennifer Jarrett sold 11,551 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $17.55, for a total transaction of $202,720.05. Following the completion of the transaction, the chief operating officer now directly owns 215,253 shares of the company’s stock, valued at $3,777,690.15. The disclosure for this sale can be found here. Insiders sold 53,455 shares of company stock valued at $1,014,779 in the last ninety days. 12.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on RCUS shares. Truist Financial reissued a “buy” rating and set a $50.00 price objective on shares of Arcus Biosciences in a report on Monday, March 25th. Wedbush reiterated an “outperform” rating and issued a $30.00 price target on shares of Arcus Biosciences in a research report on Thursday, February 22nd. Finally, Mizuho cut their price target on shares of Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, January 30th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.25.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.